Michael Yuryev, DO
Family Medicine · Brooklyn, NYNPI 1174857817
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,444 of the $3,012 with a category attached, or 81.2%. Ipsen Innovation accounts for 97.2% of it on its own, with 1 other manufacturer making up the rest.
Across 15 payments — averaging $200.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$83
Across 109 payments — averaging $5412.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Romark Laboratories, LC$303K
- GSK$231K
- Bayer$27K
- Vanda Pharmaceuticals Inc.$16K
- Avanir Pharmaceuticals, Inc.$9K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- plus $3K from 2 others
What the payments were for
- Travel & lodging$2,44481%
- Food & beverage$56819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 10 | $2,928 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
How this compares
$3,012 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $13,488 |
| JanuviaSitagliptin Phosphate | 14 | $13,464 |
| LinzessLinaclotide | 12 | $11,862 |
| Diclofenac Sodium | 11 | $6,700 |
| VascepaIcosapent Ethyl | 15 | $6,237 |
| Mesalamine | 13 | $2,706 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,564 |
| SynthroidLevothyroxine Sodium | 12 | $987 |
| Atorvastatin Calcium | 110 | $702 |
| Metoprolol Succinate | 58 | $646 |
| Losartan Potassium | 75 | $554 |
| Rosuvastatin Calcium | 49 | $407 |
| Amlodipine Besylate | 75 | $351 |
| Metformin Hcl | 43 | $274 |
| Levothyroxine Sodium | 33 | $267 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Brooklyn
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Rui TengBrooklyn$39K
- Wei WangBrooklyn$26K
- Raymond ChanBrooklyn$25K
- Mikhail KorogluyevBrooklyn$24K
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.